Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Epanova regulatory update

Omthera submitted an NDA to FDA for Epanova to treat severe hypertriglyceridemia, defined as triglyceride levels >=500

Read the full 177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE